Adenocarcinoma of the vaginal vault following prolonged unopposed oestrogen hormone replacement therapy

By Somoye GO   Gull S  

Journal of Obstetrics & Gynaecology, Vol. 25, Iss. 2, 2005-02 ,pp. : 220-221

Informa Healthcare

Access to resources Recommend Favorite

A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continuous combined estrogen-progestogen treatment

By Conner P.   Christow A.   Kersemaekers W.   Söderqvist G.   Skoog L.   Carlström K.   Tani E.   Mol-Arts M.   Schoultz B. von  

Climacteric, Vol. 7, Iss. 1, 2004-01 ,pp. : 50-58

Informa Healthcare

Access to resources Recommend Favorite

Is combined estrogen/progestogen hormone therapy worth the risk?

By Sturdee David W.   MacLennan Alastair H.  

Climacteric, Vol. 6, Iss. 3, 2003-09 ,pp. : 177-179

Informa Healthcare

Access to resources Recommend Favorite

Predictors of intentions to use hormone replacement therapy in clinical postmenopausal women

By Simpson E. E. A.  

Climacteric, Vol. 15, Iss. 2, 2012-04 ,pp. : 173-180

Informa Healthcare

Access to resources Recommend Favorite

Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations

By Pines A.   Mijatovic V.   van der Mooren M.J.   Kenemans P.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 71, Iss. 2, 1997-02 ,pp. : 193-197

Elsevier

Access to resources Recommend Favorite